Teriparatide: Uses, Evidence, and Side Effects

Osteoporosis raises the risk of fractures that can limit mobility and independence, and many people want to know what options exist beyond standard bone-density drugs. Teriparatide is one such option, a lab-made hormone therapy with a defined FDA-approved role in fracture prevention.

Key takeaways

• Teriparatide is a parathyroid hormone analog approved for specific high-risk osteoporosis populations.
• It works by binding the same receptors as natural parathyroid hormone to influence bone metabolism.
• Over 190 registered clinical trials have studied teriparatide, including head-to-head and combination studies.
• The most frequently reported issues in safety data involve pain, joint symptoms, and dizziness.
• No boxed warning is present on the current label.

What Teriparatide Is

Teriparatide belongs to a drug class called parathyroid hormone analogs. It corresponds to the 34 N-terminal amino acids of endogenous parathyroid hormone (PTH), the natural regulator of calcium and phosphate balance in bone and kidney. By binding the same high-affinity cell-surface receptors that PTH uses, teriparatide engages the body's own pathways for bone metabolism and calcium handling. It is marketed under the brand name teriparatide, and its identity is catalogued under PubChem CID 16133850.

What Teriparatide Is Approved For

Teriparatide injection is approved for postmenopausal women with osteoporosis who are at high risk for fracture, meaning they have a prior osteoporotic fracture or multiple risk factors, or who have not responded to or cannot tolerate other osteoporosis therapies. In this population, it reduces the risk of both vertebral and nonvertebral fractures. It is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who meet similar high-risk or treatment-failure criteria. A third approved use covers men and women with osteoporosis caused by long-term systemic glucocorticoid therapy at daily doses equivalent to 5 mg or more of prednisone, again in those at high risk for fracture. The current label does not carry a boxed warning.

What the Evidence Shows

More than 190 clinical trials have registered teriparatide as a study drug, reflecting broad investigation of its effects on bone. A completed Phase 4 trial examined bone modeling effects when teriparatide was combined with an antiresorptive agent. Another completed Phase 4 study compared teriparatide against denosumab for bone outcomes in postmenopausal women with osteoporosis. A completed Phase 3 trial evaluated teriparatide alongside risedronate specifically in men with osteoporosis.

Reported Side Effects

Safety surveillance data for teriparatide show a pattern dominated by musculoskeletal and neurological complaints alongside general systemic symptoms. The most frequently reported reactions include nausea (9,008 reports), arthralgia (8,703), pain in extremity (8,368), and dizziness (8,321), followed by falls (7,915), general pain (7,563), fatigue (7,210), and back pain (5,933). These figures represent counts of submitted reports, not confirmed incidence rates or established causation. The pattern suggests musculoskeletal discomfort and dizziness-related events are commonly noted by users or prescribers, but the data cannot establish how often these events are actually caused by the drug.